Editorial

Medical Research Council: Definition and classification of chronic bronchitis for clinical and epidemiological purposes. Lancet 1965; 1: 775–779

Hurd S : The impact of COPD on lung health worldwide. Chest 2000; 117 (Suppl): 1S–4S

Murray CJL Lopez AD : Evidence-based health policy: lessons from the global burden of disease study. Science 1996; 274: 740–743

NHLBI Morbidity and Mortality Chartbook, 1998. Available from URL: http://www.nhlbi.nih.gov/resources/docs/cht-book.htm

Ball P Tillotson G Wilson R : Chemotherapy for chronic bronchitis. Controversies. Presse Med 1995; 24: 189–194

Statisches Bundesamt: Gesundheitsbericht für Deutschland, 1998; pp 234–236

Wilson L Devine EB So K : Direct medical costs of chronic obstructive pulmonary disease: chronic bronchitis and emphysema. Resp Med 2000; 94: 204–213

Wilson R : The pathogenesis and management of bronchial infections: the vicious circle of respiratory decline. Rev Contemp Pharmacother 1992; 3: 103–112

Adams S Melo J Luther M Anzueto A : Antibiotics are associated with lower relapse rates in outpatients with acute exacerbations of COPD. Chest 2000; 117: 1345–1352

Landen H Möller M Tillotson GS Kubin R Höffken G : Clinical experience in Germany of treating community-acquired respiratory infections with the new 8-methoxyfluoroquinolone, moxifloxacin. J Int Med Res 2001; 29: 51–60

Lorenz J Busch W , Thate-Waschke I-M for the BRONCHIMOX Study Group: Moxifloxacin in acute exacerbations of chronic bronchitis: clinical evaluation and assessment by patients. J Int Med Res 2001; 29: 61–73

Lorenz J Thate-Waschke I-M Mast O Kubin R Rychlik R Pfeil T : Treatment outcomes in acute exacerbations of chronic bronchitis: comparison of macrolides and moxifloxacin from the patient perspective. J Int Med Res 2001; 29: 74–86

Elmes PC Fletcher CM Dutton AAC : Prophylactic use of oxytetracycline for exacerbations of chronic bronchitis. BMJ 1957; 4: 1272–1275